Boston—Neoadjuvant targeted therapy for renal cell carcinoma (RCC) is less toxic than adjuvant targeted therapy, but both should be considered in light of the re-emergence of immunotherapy according to a presentation during the 2017 annual meeting of the Society of Urologic Oncology.
Discussing the roles of neoadjuvant and adjuvant targeted therapy in RCC, presenter Mohamad E. Allaf, MD, said neoadjuvant therapy with tyrosine kinase inhibitors (TKIs) can shrink tumors, but adjuvant